Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial
Y Talmor-Barkan, NS Yacovzada… - European Heart …, 2023 - academic.oup.com
Aims The advantages of direct oral anticoagulants (DOACs) over warfarin are well
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …
Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population …
Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström, M Lund… - International journal of …, 2018 - Elsevier
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
M Jansson, S Själander, V Sjögren, H Renlund… - Thrombosis …, 2020 - Elsevier
Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …
Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients
D Menichelli, F Del Sole, A Di Rocco… - European Heart …, 2021 - academic.oup.com
Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …
Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
S Perreault, A Dragomir, R Cote… - … : The Journal of …, 2021 - Wiley Online Library
Abstract Study Objective Observational studies assessing direct oral anticoagulant (DOACs)
dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high …
dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high …
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large …
TC Villines, A Ahmad, M Petrini, W Tang… - European Heart …, 2019 - academic.oup.com
Aims We used the US Department of Defense Military Health System database to compare
the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non …
the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non …
Safety and effectiveness of dabigatran and other direct oral anticoagulants compared with warfarin in patients with atrial fibrillation
KF Huybrechts, C Gopalakrishnan… - Clinical …, 2020 - Wiley Online Library
The study objective was to evaluate the safety and effectiveness of dabigatran and other
direct oral anticoagulants (DOACs) compared with warfarin among patients with nonvalvular …
direct oral anticoagulants (DOACs) compared with warfarin among patients with nonvalvular …
[HTML][HTML] Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
A Briasoulis, Y Gao, C Inampudi, P Alvarez… - BMC cardiovascular …, 2020 - Springer
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF)
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: a real …
XL Marston, R Wang, YC Yeh, L Zimmermann… - International journal of …, 2022 - Elsevier
Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …